Tilray Medical Launches its First Commercial “Grown in Germany” Medical Cannabis Products Under its Newly Expanded Cultivation License
Tilray Medical has launched its first commercial German-grown medical cannabis products from its Aphria RX facility under a newly issued cultivation license. The company received Germany's first medical cannabis cultivation license under MedCanG on July 15, 2024, allowing them to cultivate and manufacture a broad range of medical cannabis products. The strains selected for cultivation at the indoor facility are derived from top-performing varieties popular with patients in Canada. This development strengthens Tilray's position in German medical cannabis cultivation, production, and distribution.
Tilray Medical ha lanciato i suoi primi prodotti di cannabis medica coltivati in Germania dalla sua struttura Aphria RX, sotto una nuova licenza di coltivazione. L'azienda ha ricevuto la prima licenza di coltivazione di cannabis medica in Germania secondo MedCanG il 15 luglio 2024, che consente loro di coltivare e produrre una vasta gamma di prodotti di cannabis medica. Le varietà selezionate per la coltivazione nella struttura indoor derivano da varietà di alta qualità, apprezzate dai pazienti in Canada. Questo sviluppo rafforza la posizione di Tilray nella coltivazione, produzione e distribuzione di cannabis medica in Germania.
Tilray Medical ha lanzado sus primeros productos de cannabis médica cultivados en Alemania desde su instalación Aphria RX bajo una nueva licencia de cultivo. La empresa recibió la primera licencia de cultivo de cannabis médico en Alemania bajo MedCanG el 15 de julio de 2024, lo que les permite cultivar y fabricar una amplia gama de productos de cannabis médico. Las variedades seleccionadas para el cultivo en la instalación indoor provienen de variedades de alto rendimiento que son populares entre los pacientes en Canadá. Este desarrollo refuerza la posición de Tilray en el cultivo, producción y distribución de cannabis médico en Alemania.
틸레이 메디컬은 새롭게 발급된 재배 라이선스에 따라 아프리아 RX 시설에서 독일에서 재배된 첫 상업 의료용 대마초 제품을 출시했습니다. 이 회사는 2024년 7월 15일 MedCanG에 따라 독일 최초의 의료용 대마초 재배 라이선스를 받아 광범위한 의료용 대마초 제품을 재배하고 제조할 수 있게 되었습니다. 실내 시설에서 재배할 선택된 품종은 캐나다의 환자에게 인기 있는 최고의 품종에서 왔습니다. 이 개발은 틸레이의 독일 의료용 대마초 재배, 생산 및 유통에서의 입지를 강화합니다.
Tilray Medical a lancé ses premiers produits de cannabis médicinal cultivés en Allemagne depuis son installation Aphria RX, sous une nouvelle licence de culture. L'entreprise a reçu la première licence de culture de cannabis médicinal en Allemagne sous MedCanG le 15 juillet 2024, lui permettant de cultiver et de fabriquer une large gamme de produits de cannabis médicinal. Les variétés choisies pour la culture dans l'installation intérieure sont dérivées de variétés performantes appréciées par les patients au Canada. Ce développement renforce la position de Tilray dans la culture, la production et la distribution de cannabis médicinal en Allemagne.
Tilray Medical hat seine ersten kommerziellen in Deutschland angebauten medizinischen Cannabisprodukte aus seiner Aphria RX-Anlage unter einer neu erteilten Anbauerlaubnis auf den Markt gebracht. Das Unternehmen erhielt am 15. Juli 2024 die erste medizinische Cannabis-Anbauerlaubnis in Deutschland gemäß MedCanG, die es ihnen ermöglicht, eine Vielzahl von medizinischen Cannabisprodukten anzubauen und herzustellen. Die für die Indoor-Anlage ausgewählten Sorten stammen von leistungsstarken Variationen, die bei Patienten in Kanada beliebt sind. Diese Entwicklung stärkt die Position von Tilray im Anbau, in der Produktion und im Vertrieb von medizinischem Cannabis in Deutschland.
- First company to receive German medical cannabis cultivation license under MedCanG
- Successfully launched locally grown medical cannabis products in Germany
- Expanded manufacturing capabilities for commercial medical cannabis in German market
- None.
Insights
The launch of locally grown medical cannabis products in Germany represents a significant strategic advantage for Tilray. Being first-to-market with German-grown products under the new MedCanG license creates a competitive moat in Europe's largest medical cannabis market. The facility's ability to cultivate proven Canadian strains locally eliminates import dependencies and should improve margins while ensuring consistent supply.
This development strengthens Tilray's European infrastructure and positions them to capture market share as Germany moves toward potential adult-use legalization. The local production capability also provides a springboard for expansion into other EU markets, leveraging Germany's strict quality standards as a mark of excellence. However, the immediate financial impact may be gradual as the medical cannabis market develops.
NEUMÜNSTER, Germany, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray Brands") (NASDAQ: TLRY and TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced the launch of its first commercial German grown medical cannabis flowers from its Aphria RX GmbH (“Aphria RX”) facility. This launch marks the first medical cannabis products to be grown in Germany by Aphria RX under the newly issued medical cannabis cultivation license under MedCanG.
On July 15, 2024, Tilray Medical was the first to receive a new cannabis cultivation license issued under MedCanG. This license allows Aphria RX to cultivate and manufacture a broad range of commercially available medical cannabis in Germany. The strains to be grown at this indoor facility have been carefully selected from top performing varieties popular with patients across Canada.
Tilray's Chief Strategy Officer and Head of International, Denise Faltischek, said, "We are excited to launch our Made in Germany premium cannabis products, which marks a significant milestone in our mission to deliver the highest-quality medical cannabis products to patients in Germany. This not only serves to expand Tilray's leadership in medical cannabis cultivation, production and distribution in Germany but also proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality products that address the needs of patients. We reiterate our appreciation for the trust that the German Government has placed in Tilray, and we are proud of our Aphria RX team for their groundbreaking work in medical cannabis cultivation and patient care."
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information:
Media: news@tilray.com
Investors: investors@tilray.com
FAQ
When did Tilray (TLRY) receive its German cannabis cultivation license?
What products is Tilray (TLRY) growing in its German facility?
Where is Tilray's (TLRY) German cannabis cultivation facility located?
